应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02196 复星医药
未开盘 05-03 16:09:00
12.580
-0.060
-0.47%
最高
12.860
最低
12.420
成交量
176.53万
今开
12.680
昨收
12.640
日振幅
3.48%
总市值
336.19亿
流通市值
69.43亿
总股本
26.72亿
成交额
2,217万
换手率
0.32%
流通股本
5.52亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
《大行》高盛降复星医药(02196.HK)目标价至20.07元 首季毛利受压
阿斯达克财经 · 05-02
《大行》高盛降复星医药(02196.HK)目标价至20.07元 首季毛利受压
医美概念股走高 四环医药(00460)涨8.77% 国金证券指医美行业仍处于高景气发展阶段
金吾财讯 · 05-02
医美概念股走高 四环医药(00460)涨8.77% 国金证券指医美行业仍处于高景气发展阶段
复星医药今年一季度净利润下滑近四成
新京报网 · 05-02
复星医药今年一季度净利润下滑近四成
野村:复星核心业务增长明确,重申“增持”评级
中金在线 · 05-01
野村:复星核心业务增长明确,重申“增持”评级
复星国际:附属公司复星高科一季度归母净利润同比减少25.4%
界面 · 04-30
复星国际:附属公司复星高科一季度归母净利润同比减少25.4%
智通AH统计|4月30日
智通财经 · 04-30
智通AH统计|4月30日
南向资金4月29日净买入复星医药25.50万股 连续3日增持
自选股智能写手 · 04-30
南向资金4月29日净买入复星医药25.50万股 连续3日增持
复星医药获融资买入0.37亿元,近三日累计买入0.65亿元
金融界 · 04-30
复星医药获融资买入0.37亿元,近三日累计买入0.65亿元
《业绩》复星医药(02196.HK)首季净利润6.1亿人民币 倒退38.2%
阿斯达克财经 · 04-30
《业绩》复星医药(02196.HK)首季净利润6.1亿人民币 倒退38.2%
复星医药Q1财报:实现营收101.57亿元,将斥资亿元回购
东方网 · 04-29
复星医药Q1财报:实现营收101.57亿元,将斥资亿元回购
复星医药(600196.SH)发布一季度业绩,净利润6.1亿元
智通财经 · 04-29
复星医药(600196.SH)发布一季度业绩,净利润6.1亿元
复星医药(02196):复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款
智通财经网 · 04-29
复星医药(02196):复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款
复星医药(02196)第一季度实现归母净利润6.1亿元
智通财经 · 04-29
复星医药(02196)第一季度实现归母净利润6.1亿元
复星医药(02196.HK)第一季度净利润6.10亿元 同比减少38.22%
格隆汇资讯 · 04-29
复星医药(02196.HK)第一季度净利润6.10亿元 同比减少38.22%
V观财报|复星医药一季度营收净利双降:新冠产品收入大降
中新经纬 · 04-29
V观财报|复星医药一季度营收净利双降:新冠产品收入大降
复星医药2024年一季报:实现营收101.57亿元
南方财经网 · 04-29
复星医药2024年一季报:实现营收101.57亿元
图解复星医药一季报:第一季度单季净利润同比减38.22%
证券之星 · 04-29
图解复星医药一季报:第一季度单季净利润同比减38.22%
财报速递:复星医药2024年一季度净利润6.10亿元
同花顺资讯 · 04-29
财报速递:复星医药2024年一季度净利润6.10亿元
复星医药(02196,600196.SH)2024一季报:创新成果加速兑现,多款新品全面推进商业化进程
智通财经 · 04-29
复星医药(02196,600196.SH)2024一季报:创新成果加速兑现,多款新品全面推进商业化进程
复星医药:一季度净利润6.1亿元 同比下降38.22%
21世纪经济报道 · 04-29
复星医药:一季度净利润6.1亿元 同比下降38.22%
暂无数据
公司概况
公司名称:
复星医药
所属市场:
SEHK
上市日期:
--
主营业务:
上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。
发行价格:
--
{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":12.58,"timestamp":1714723740030,"preClose":12.64,"halted":0,"volume":1765312,"delay":0,"floatShares":551940500,"shares":2672398711,"eps":0.97486013,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.06,"latestTime":"05-03 16:09:00","open":12.68,"high":12.86,"low":12.42,"amount":22170691,"amplitude":0.03481,"askPrice":12.58,"askSize":11000,"bidPrice":12.56,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.8178273452397693,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":12.64,"dividendRate":0.023361,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.49188551841282024,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":23.67,"timestamp":1714460401000,"preClose":23.71,"halted":0,"volume":9600485,"delay":0,"premium":"-51.27"}},"requestUrl":"/m/hq/s/02196/tweets","defaultTab":"tweets","newsList":[{"id":"2432665647","title":"《大行》高盛降复星医药(02196.HK)目标价至20.07元 首季毛利受压","url":"https://stock-news.laohu8.com/highlight/detail?id=2432665647","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432665647?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:22","pubTimestamp":1714634520,"startTime":"0","endTime":"0","summary":"高盛发表报告指出,复星医药(02196.HK) 今年首季收入按年跌6.8%至101亿元人民币,略低于该行预期的107亿元人民币。在剔除疫情产品及收购影响的情况下,现有产品首季增长约5%。集团季内盈利按年跌38.2%至6.1亿元人民币,毛利受压。该行预期,复星医药次季收入增长将改善至4%,下半年将提高至10%。另对其2024至2026年盈利预测下调6.3%、6.5%及2.6%,以反映首季疲弱的业绩。该行对复星医药评级“中性”,目标价由21.53元下调至20.07元。(jl/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-02 12:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346976/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432643125","title":"医美概念股走高 四环医药(00460)涨8.77% 国金证券指医美行业仍处于高景气发展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2432643125","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2432643125?lang=zh_cn&edition=full","pubTime":"2024-05-02 14:06","pubTimestamp":1714630013,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股走高,四环医药(00460)涨8.77%,复锐医疗科技(01696)涨8.15%,三生制药(01530)涨5.41%,医思健康(02138)涨5.34%,康哲药业(00867)涨4.56%,复星医药(02196)涨2.76%。国金证券表示,看好兼具技术、产品、品牌储备的国内医美龙头。现阶段受到情绪面的影响,国内医美板块估值已经回调至相对低位。展望国内医美行业未来发展,该行认为行业仍处于高景气发展阶段。未来我国医美行业发展有望受益于合规产品占比提升与医美渗透率提升的双重驱动,竞争格局不断优化,新需求持续放量,行业业绩和估值有较大提升空间。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936162","is_publish_highlight":false,"gpt_icon":0},{"id":"2432609756","title":"复星医药今年一季度净利润下滑近四成","url":"https://stock-news.laohu8.com/highlight/detail?id=2432609756","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2432609756?lang=zh_cn&edition=full","pubTime":"2024-05-02 09:15","pubTimestamp":1714612500,"startTime":"0","endTime":"0","summary":"新京报讯 4月30日,复星医药发布2024年第一季度经营业绩,报告期内实现营收101.57亿元,同比下滑6.56%;归属于上市公司股东的净利润为6.1亿元,同比下滑38.22%。复星医药表示,营收下滑,与2024年阿兹夫定片等新冠相关产品收入同比大幅下降有关。归属于上市公司股东的净利润同比减少,除新冠产品收入同比大幅下滑导致相应利润减少外,还受到Gland Pharma并购Cenexi的摊销及Cenexi的运营亏损等影响。报告期内,复星医药研发费用8.3亿元,多款创新产品获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020916487a57e3b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020916487a57e3b6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432776577","title":"野村:复星核心业务增长明确,重申“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2432776577","media":"中金在线","top":-1,"share":"https://www.laohu8.com/m/news/2432776577?lang=zh_cn&edition=full","pubTime":"2024-05-01 21:33","pubTimestamp":1714570381,"startTime":"0","endTime":"0","summary":"4月30日,野村东方国际证券发表研究报告指,复星国际有限公司聚焦核心业务战略成效显著,核心业务增长明确,尤以复星旅文增长势头强劲,因此重申复星国际“增持”评级。野村认为消费复苏趋势明确,尤其旅文板块业绩亮眼。野村认为复星国际业务发展向好,给予目标价5.59 港元,潜在上行空间为19.85%,维持“增持”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012140368b6a0215&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012140368b6a0215&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431391512","title":"复星国际:附属公司复星高科一季度归母净利润同比减少25.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431391512","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2431391512?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:20","pubTimestamp":1714468811,"startTime":"0","endTime":"0","summary":"复星国际4月30日在港交所公告,公司附属公司上海复星高科技(集团)有限公司(简称“复星高科”)2024年第一季度营业收入约321.1亿元,同比增长7.3%;归母净利润4308.4万元,同比减少25.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301720117925760f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301720117925760f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431676853","title":"智通AH统计|4月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=2431676853","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431676853?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:15","pubTimestamp":1714464905,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止4月30日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1073.91%、760.90%、616.97%;招商银行、比亚迪股份、紫金矿业分列AH溢价率末三位,溢价率分别为19.65%、21.39%、21.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116187.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431807773","title":"南向资金4月29日净买入复星医药25.50万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431807773","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431807773?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:31","pubTimestamp":1714440679,"startTime":"0","endTime":"0","summary":"4月29日, 南向资金增持复星医药25.50万股,连续3日增持。截止当日收盘,港股通共持有复星医药25441.81万股,占流通股46.08%。复星医药近5个交易日上涨4.74%,港股通累计增持147.20万股;近20个交易日下跌2.67%,港股通累计增持1536.30万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300947358b643326&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300947358b643326&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431898808","title":"复星医药获融资买入0.37亿元,近三日累计买入0.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431898808","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431898808?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:25","pubTimestamp":1714436713,"startTime":"0","endTime":"0","summary":"4月29日,沪深两融数据显示,复星医药获融资买入额0.37亿元,居两市第345位,当日融资偿还额0.38亿元,净卖出74.48万元。最近三个交易日,25日-29日,复星医药分别获融资买入0.10亿元、0.18亿元、0.37亿元。融券方面,当日融券卖出0.89万股,净买入3.13万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300826548b63f7fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300826548b63f7fe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431897420","title":"《业绩》复星医药(02196.HK)首季净利润6.1亿人民币 倒退38.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431897420","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431897420?lang=zh_cn&edition=full","pubTime":"2024-04-30 00:23","pubTimestamp":1714407780,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布3月止第一季度报告,按中国会计准则,实现营业收入101.57亿人民币(下同),按年下降6.6%。归属股东净利润6.1亿元,倒退38.2%,主要是今年新冠相关产品销售收入大幅下降,以及并购Cenexi的摊销及运营亏损;每股收益23分。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-29 16:25。)过往派息公布日期派息事项派息内容2024/03/26末期业绩普通股息:人民币 0.272023/10/30第三季业绩无派息2023/08/29中期业绩无派息2023/04/28第一季业绩无派息 AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346055/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431856556","title":"复星医药Q1财报:实现营收101.57亿元,将斥资亿元回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2431856556","media":"东方网","top":-1,"share":"https://www.laohu8.com/m/news/2431856556?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:32","pubTimestamp":1714390366,"startTime":"0","endTime":"0","summary":"财报显示,报告期内,复星医药实现营业收入人民币101.57亿元,归母净利润6.1亿元,重点创新品种收入保持快速增长,收入结构持续优化;报告期内,经营活动产生的现金流量净额9.17亿元,同比增长5.05%。财报显示,今年第一季度,复星医药多款创新产品获批上市,并对上市新品的商业化进程提速。值得注意的是,复星医药也在季报中公布了回购计划。截至4月29日收盘,复星医药报23.71元/股,上涨2.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292011158b61fc4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292011158b61fc4e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431183146","title":"复星医药(600196.SH)发布一季度业绩,净利润6.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431183146","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431183146?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:57","pubTimestamp":1714388230,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)发布2024年第一季度报告,该公司营业收入为101.57亿元,归属于上市公司股东的净利润6.1亿元,归属于上市公司股东的扣除非经常性损益的净利润6.09亿元,基本每股收益0.23元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114649.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431883946","title":"复星医药(02196):复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款","url":"https://stock-news.laohu8.com/highlight/detail?id=2431883946","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431883946?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:46","pubTimestamp":1714387592,"startTime":"0","endTime":"0","summary":"复星医药(02196)发布公告,为满足复星凯特生物科技有限公司(以下简称“复星凯特...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114612.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431834892","title":"复星医药(02196)第一季度实现归母净利润6.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431834892","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431834892?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:42","pubTimestamp":1714387344,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药 发布2024年第一季度业绩,该集团期内取得营业收入101.57亿元;归属于上市公司股东的净利润6.1亿元;基本每股收益0.23元。围绕提高临床服务能力及销售团队专业能力和灵活性,采取优化营销组织架构与人员结构、进行渠道整合以降低服务费、根据市场需要调整营销模式以及费用精细化管理等措施,使销售费用率同比下降了2个百分点。报告期内共取得14张注册证,其中三类证12张。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291858178b61abd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291858178b61abd3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431681839","title":"复星医药(02196.HK)第一季度净利润6.10亿元 同比减少38.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431681839","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431681839?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:40","pubTimestamp":1714387205,"startTime":"0","endTime":"0","summary":"格隆汇4月29日丨复星医药发布公告,2024年第一季度,集团实现营业收入101.57亿元,较上年同期减少6.56%。报告期内,集团实现归属于上市公司股东的净利润6.10亿元,同比减少38.22%;其中,实现归属于上市公司股东的扣除非经常性损益的净利润6.09亿元,同比减少33.81%。报告期内,本集团非经常性损益为0.01亿元,同比减少0.66亿元,变动原因主要系上年同期包含天津药业等非核心资产出售收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042918401887bedab0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042918401887bedab0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431330318","title":"V观财报|复星医药一季度营收净利双降:新冠产品收入大降","url":"https://stock-news.laohu8.com/highlight/detail?id=2431330318","media":"中新经纬","top":-1,"share":"https://www.laohu8.com/m/news/2431330318?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:11","pubTimestamp":1714385484,"startTime":"0","endTime":"0","summary":"中新经纬4月29日电 29日,复星医药发布一季报显示,公司2024年一季度营收101.57亿元,同比减少6.56%;归属于上市公司股东的净利润(下称净利润)6.10亿元,同比减少38.22%。 复星医药公告截图 复星医药称,报告期内,本集团实现营业收入101.57亿元,同比减少主要由于2023年第一季度营业收入中包含捷倍安(阿兹夫定片)等...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/ODLbrRJ9KjoT0RlGeA6teLhbMasBfO0SYSw1bKnIPJwhQAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/ODLbrRJ9KjoT0RlGeA6teLhbMasBfO0SYSw1bKnIPJwhQAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240429A07VQX00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240429A07VQX00","is_publish_highlight":false,"gpt_icon":0},{"id":"2431833998","title":"复星医药2024年一季报:实现营收101.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431833998","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431833998?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:06","pubTimestamp":1714385160,"startTime":"0","endTime":"0","summary":"南方财经4月29日电,复星医药公布2024年第一季度经营业绩显示,报告期内,复星医药实现营业收入101.57亿元,重点创新品种收入保持快速增长,收入结构持续优化。2024年第一季度,包括自主研发的冻干人用狂犬病疫苗(Vero细胞)等多款创新产品在国内获批上市。此外,2024年4月,注射用曲妥珠单抗(中国境内商品名:汉曲优)获美国FDA批准上市,用于辅助治疗HER2过表达乳腺癌、治疗HER2过表达转移性乳腺癌、以及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌,成为首个在中国、欧盟、美国获批的国产生物类似药。(21世纪经济报道)(文章来源:南方财经网)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291808408b61838b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291808408b61838b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431880817","title":"图解复星医药一季报:第一季度单季净利润同比减38.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431880817","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431880817?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:45","pubTimestamp":1714383957,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药2024年一季报显示,公司主营收入101.57亿元,同比下降6.56%;归母净利润6.1亿元,同比下降38.22%;扣非净利润6.09亿元,同比下降33.81%;负债率49.42%,投资收益3.36亿元,财务费用2.8亿元,毛利率50.01%。财报数据概要请见下图:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291754218b617272&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291754218b617272&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431884350","title":"财报速递:复星医药2024年一季度净利润6.10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431884350","media":"同花顺资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431884350?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:27","pubTimestamp":1714382862,"startTime":"0","endTime":"0","summary":"4月30日,A股上市公司复星医药发布2024年一季度业绩报告。其中,净利润6.10亿元,同比下降38.22%。净利润6.10亿元,同比下降38.22%从营收和利润方面看,公司本报告期实现营业总收入101.57亿元,同比下降6.56%,净利润6.10亿元,同比下降38.22%,基本每股收益为0.23元。综合来看,复星医药总体财务状况尚可,当前总评分为2.08分,在所属的化学制药行业的156家公司中排名靠后。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291727247a5704f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291727247a5704f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431884368","title":"复星医药(02196,600196.SH)2024一季报:创新成果加速兑现,多款新品全面推进商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2431884368","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431884368?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:21","pubTimestamp":1714382486,"startTime":"0","endTime":"0","summary":"4月29日,复星医药公布了2024年第一季度经营业绩。复星医药自主研发的F-i6000全自动化学发光免疫分析仪获批上市,F-i6000为超高速免疫分析仪,具有完全自主知识产权,该产品可接入实验室自动化系统,提供整体解决方案。根据复星医药子公司复宏汉霖的2024年一季报显示,汉曲优实现中国境内销售收入约人民币6.71亿元。同时,复星医药将推进业务聚焦,致力成为全球医疗健康市场一流企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291729328b61530f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291729328b61530f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431843638","title":"复星医药:一季度净利润6.1亿元 同比下降38.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431843638","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2431843638?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:08","pubTimestamp":1714381680,"startTime":"0","endTime":"0","summary":"南方财经4月29日电,复星医药发布一季报,一季度实现净利润6.1亿元,同比下降38.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042917092087be75c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042917092087be75c8&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0261},{"period":"1month","weight":-0.0063},{"period":"3month","weight":-0.0498},{"period":"6month","weight":-0.3185},{"period":"1year","weight":-0.4346},{"period":"ytd","weight":-0.26}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.049465},{"month":2,"riseRate":0.75,"avgChangeRate":0.030196},{"month":3,"riseRate":0.666667,"avgChangeRate":0.05388},{"month":4,"riseRate":0.416667,"avgChangeRate":0.038788},{"month":5,"riseRate":0.5,"avgChangeRate":0.025836},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.041074},{"month":7,"riseRate":0.545455,"avgChangeRate":0.017881},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.057829},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.025941},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035528},{"month":11,"riseRate":0.5,"avgChangeRate":0.052861},{"month":12,"riseRate":0.5,"avgChangeRate":0.024492}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}